文献速递临床微生物临床免疫

应用商业化定量酶免疫分析法检测尿液中皮炎芽生菌抗原

Detection of Blastomyces dermatitidis Antigen in Urine Using a Commercially Available Quantitative Enzyme Immunoassay.
PubMed 文献 · J Clin Microbiol · 2021-08-04

本研究评估Gotham Biotech的分析物特异性试剂定量检测尿液中皮炎芽生菌半乳甘露聚糖(GM)的性能,并与MiraVista定量EIA比较。对232例既往MiraVista检测的残余尿标本用Gotham EIA检测,阳性、阴性和总符合率分别为97.4%、100%和99.1%,但定量抗原水平相关性低(R2=0.20)。实验室应用Gotham EIA后前50例患者中3例阳性,包括2例培养确诊芽生菌病和1例组织胞浆菌病。

要点

  • Gotham与MiraVista EIA检测尿液皮炎芽生菌GM的定性符合率高。
  • 两种EIA定量抗原水平相关性低(R2=0.20)。
  • 组织胞浆菌病患者中Gotham EIA阳性率低于MiraVista EIA。

核心结论

  • Gotham与MiraVista定量EIA检测尿液皮炎芽生菌GM的定性性能相当。

研究设计与样本

  • 用Gotham EIA检测232例既往经MiraVista EIA检测的残余尿标本,并比较两者定性符合率和定量相关性。
  • 实验室应用Gotham EIA后回顾性分析前50例患者(51份样本)的病历。

主要发现

  • Gotham EIA与MiraVista EIA的阳性符合率为97.4%(74/76),阴性符合率为100%(156/156),总符合率为99.1%(230/232)。
  • 两种EIA定量皮炎芽生菌抗原水平相关性低(R2=0.20)。
  • 36例有病历患者中,4例确诊芽生菌病且两种EIA均阳性;9例组织胞浆菌病中Gotham和MiraVista EIA分别阴性44.4%(4/9)和22.2%(2/9);其余23例两种EIA均阴性。
  • 应用Gotham EIA后前50例患者中3/50(6%)样本阳性,包括2份来自培养确诊芽生菌病患者和1份来自组织胞浆菌病患者(该患者MiraVista芽生菌EIA亦阳性)。

临床怎么用

  • Gotham EIA可用于尿液皮炎芽生菌GM的定性检测,但定量结果与MiraVista EIA相关性低,不宜直接互换比较。
  • 组织胞浆菌病患者中Gotham EIA阳性率可能低于MiraVista EIA,结果解释需结合临床。

局限性

  • 定量相关性分析仅基于232份样本,且定量水平相关性低。
  • 病历回顾仅覆盖36例患者,应用后评估仅50例患者,样本量有限。
  • 未报告两种EIA在确诊芽生菌病患者中的敏感性比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Laboratory diagnosis of blastomycosis relies on a combination of methods, including antigen detection. We assessed the performance of analyte-specific reagents from Gotham Biotech (Portland, ME) for quantitative detection of Blastomyces dermatitidis galactomannan (GM) in urine using an enzyme immunoassay (EIA) compared to the Blastomyces quantitative EIA from MiraVista Diagnostics (Indianapolis, IN). Residual urine from 232 unique patients previously tested by the MiraVista assay was evaluated using the Gotham EIA, which showed 97.4% (74/76), 100% (156/156), and 99.1% (230/232) positive, negative, and overall agreement, respectively. Correlation between the quantitative B. dermatitidis antigen levels by the Gotham and MiraVista EIAs was low (R2 = 0.20). Medical records were available for 36 of the 232 patients, among whom four had confirmed blastomycosis and both the Gotham and MiraVista EIAs were positive. Nine of these patients had histoplasmosis, and the Gotham and MiraVista EIAs yielded negative results in 44.4% (4/9) and 22.2% (2/9) of cases, respectively. Both assays were negative in the remaining 23 patients. After laboratory implementation of the Gotham EIA, chart reviews were performed on the first 50 unique patients (51 samples) tested by the assay in our hospital. Among these, 3/50 (6%) samples were positive by the Gotham EIA, including two samples from a patient with culture-confirmed blastomycosis and one from a patient with histoplasmosis (also positive by the MiraVista Blastomyces EIA). All remaining patients were negative by the Gotham EIA and had alternative diagnoses. Our findings show comparable performance between the Gotham and MiraVista quantitative EIAs for detection of B. dermatitidis GM in urine.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Theel ES, Rodino KG, Granger D, et al. Detection of Blastomyces dermatitidis Antigen in Urine Using a Commercially Available Quantitative Enzyme Immunoassay. J Clin Microbiol. 2021. PMID: 34346719. doi:10.1128/JCM.01444-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。